{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178504","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.059382+00:00","generated_at":"2026-05-17T14:47:08.739641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha Q2 net loss $26.9M; TSHA-102 pivotal trial site activation begun, enrollment Q4 2025","bullets":["Cash $312.8M after $230M follow-on offering; runway extended into 2028.","Net loss $26.9M ($0.09/share) vs $20.9M ($0.09) in Q2 2024.","REVEAL pivotal trial site activation commenced; FDA and Health Canada feedback received.","100% response rate on primary endpoint in Part A; no treatment-related SAEs or DLTs in 12 patients.","New supplemental clinical data from Part A expected in Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178504","json":"https://secwatch.observer/filing/0001193125-25-178504.json","markdown":"https://secwatch.observer/filing/0001193125-25-178504.md","text":"https://secwatch.observer/filing/0001193125-25-178504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/0001193125-25-178504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:47:08.739641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}